Jeffrey J Teuteberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6387377/publications.pdf

Version: 2024-02-01

186209 82499 5,479 76 28 72 citations h-index g-index papers 76 76 76 5287 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.3	1,385
2	Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 1316-1324.	0.4	837
3	Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation. New England Journal of Medicine, 2010, 362, 1890-1900.	13.9	452
4	The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. Journal of Heart and Lung Transplantation, 2019, 38, 114-126.	0.3	349
5	The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Annals of Thoracic Surgery, 2020, 109, 649-660.	0.7	323
6	Right ventricular failure after left ventricular assist devices. Journal of Heart and Lung Transplantation, 2015, 34, 1123-1130.	0.3	321
7	The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships. Annals of Thoracic Surgery, 2019, 107, 341-353.	0.7	177
8	Incidence and Patterns of Adverse Event Onset During the First 60 Days After Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2009, 88, 1162-1170.	0.7	160
9	Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium. Journal of Heart and Lung Transplantation, 2020, 39, 735-750.	0.3	101
10	Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. JAMA Cardiology, 2020, 5, 703.	3.0	93
11	Early Right Ventricular Assist Device Use in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2017, 10, .	1.6	89
12	Impact of Hemodynamic Ramp Test-Guided HVAD Speed and Medication Adjustments on Clinical Outcomes. Circulation: Heart Failure, 2019, 12, e006067.	1.6	60
13	Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Circulation: Heart Failure, 2019, 12, e006635.	1.6	58
14	Survival Outcomes After Heart Transplantation. Circulation: Heart Failure, 2019, 12, e006218.	1.6	56
15	Evolution of Late Right HeartÂFailure With Left Ventricular Assist Devices and AssociationÂWithÂOutcomes. Journal of the American College of Cardiology, 2021, 78, 2294-2308.	1.2	48
16	Early adverse events as predictors of 1-year mortality during mechanical circulatory support. Journal of Heart and Lung Transplantation, 2010, 29, 981-988.	0.3	47
17	Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. Journal of Heart and Lung Transplantation, 2019, 38, 408-417.	0.3	47
18	Shortâ€term outcomes of <i>en bloc</i> combined heart and liver transplantation in the failing Fontan. Clinical Transplantation, 2019, 33, e13540.	0.8	46

#	Article	IF	Citations
19	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. JACC: Heart Failure, 2018, 6, 771-779.	1.9	45
20	The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. Critical Care Medicine, 2021, 49, 1293-1302.	0.4	41
21	Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2019, 12, e005537.	1.6	38
22	INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. Journal of Heart and Lung Transplantation, 2020, 39, 16-26.	0.3	38
23	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. Journal of Heart and Lung Transplantation, 2021, 40, 926-935.	0.3	36
24	Current Use of Hearts From Hepatitis C Viremic Donors. Circulation: Heart Failure, 2018, 11, e005276.	1.6	35
25	Outcomes in patients undergoing cardiac retransplantation: A propensity matched cohort analysis of the UNOS Registry. Journal of Heart and Lung Transplantation, 2019, 38, 1067-1074.	0.3	33
26	Risk evaluation using gene expression screening to monitor for acute cellular rejection in heart transplant recipients. Journal of Heart and Lung Transplantation, 2019, 38, 51-58.	0.3	33
27	Predicting post-operative right ventricular failure using video-based deep learning. Nature Communications, 2021, 12, 5192.	5.8	32
28	Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clinical Transplantation, 2008, 22, 730-737.	0.8	31
29	Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. Journal of Heart and Lung Transplantation, 2020, 39, 619-626.	0.3	31
30	Concordance of Treatment Effect: An Analysis of The Society of Thoracic Surgeons Intermacs Database. Annals of Thoracic Surgery, 2022, 113, 1172-1182.	0.7	29
31	Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. Canadian Journal of Cardiology, 2019, 35, 104.e1-104.e3.	0.8	24
32	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2021, 14, e007957.	1.6	24
33	To kidney or not to kidney: Applying lessons learned from the simultaneous liverâ€kidney transplant policy to simultaneous heartâ€kidney transplantation. Clinical Transplantation, 2020, 34, e13878.	0.8	23
34	Gene expression profiling to study racial differences after heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 970-977.	0.3	21
35	Accepting hepatitis C virus-infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experience. Clinical Transplantation, 2018, 32, e13308.	0.8	21
36	Gene expression profiling and racial disparities in outcomes after heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 820-829.	0.3	18

#	Article	IF	CITATIONS
37	Donor and Recipient Size Matching in Heart Transplantation With Predicted Heart and Lean Body Mass. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 158-167.	0.4	17
38	Right ventricular load adaptability metrics in patients undergoing left ventricular assist device implantation. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1023-1033.e4.	0.4	16
39	Substantial Reduction in Driveline Infection Rates With the Modification of Driveline Dressing Protocol. Journal of Cardiac Failure, 2018, 24, 746-752.	0.7	15
40	Innovations in Ventricular Assist Devices for End-Stage Heart Failure. Annual Review of Medicine, 2019, 70, 33-44.	5.0	14
41	Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials. Journal of Heart and Lung Transplantation, 2020, 39, 639-647.	0.3	14
42	Use of direct oral anticoagulants after heart transplantation. Journal of Heart and Lung Transplantation, 2020, 39, 399-401.	0.3	14
43	Impact of thoracotomy approach on right ventricular failure and length of stay in left ventricular assist device implants: an intermacs registry analysis. Journal of Heart and Lung Transplantation, 2021, 40, 981-989.	0.3	13
44	Outcomes of patients with infection related to a ventricular assist device after heart transplantation. Clinical Transplantation, 2019, 33, e13692.	0.8	12
45	Perceived Generational, Geographic, and Sex-Based Differences in Choosing a Career in Advanced Heart Failure. Circulation: Heart Failure, 2019, 12, e005754.	1.6	11
46	Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. ASAIO Journal, 2019, 65, 436-441.	0.9	10
47	Outcomes of Heart Failure Admissions Under Observation Versus Short Inpatient Stay. Journal of the American Heart Association, $2018, 7, .$	1.6	9
48	Impact of cytomegalovirus infection on gene expression profile in heart transplant recipients. Journal of Heart and Lung Transplantation, 2021, 40, 101-107.	0.3	9
49	Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant. Journal of Heart and Lung Transplantation, 2021, , .	0.3	8
50	Impact of diabetes mellitus on clinical outcomes after heart transplantation. Clinical Transplantation, 2021, 35, e14460.	0.8	8
51	Defining Optimal Outcomes in Patients with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 397-404.	0.9	8
52	Parvovirus B19â€induced severe anemia in heart transplant recipients: Case report and review of the literature. Clinical Transplantation, 2019, 33, e13498.	0.8	7
53	Interpreting Neurologic Outcomes in a Changing Trial Design Landscape: An Analysis of HeartWare Left Ventricular Assist Device Using a Hybrid Intention to Treat Population. ASAIO Journal, 2019, 65, 293-296.	0.9	7
54	Risk factors for early development of cardiac allograft vasculopathy by intravascular ultrasound. Clinical Transplantation, 2020, 34, e14098.	0.8	7

#	Article	IF	CITATIONS
55	Long-term survival in patients with post-LVAD right ventricular failure: multi-state modelling with competing outcomes of heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 778-785.	0.3	7
56	Combining donor derived cell free DNA and gene expression profiling for nonâ€invasive surveillance after heart transplantation. Clinical Transplantation, 2023, 37, e14699.	0.8	7
57	Infectious complications after heart transplantation in patients screened with gene expression profiling. Journal of Heart and Lung Transplantation, 2019, 38, 611-618.	0.3	6
58	Recent Trends of Infectious Complications Following Heart Transplantation. Transplantation, 2020, 104, e284-e294.	0.5	6
59	Outcomes Among Patients With Left Ventricular Assist Devices Receiving Maintenance Outpatient Hemodialysis: A Case Series. American Journal of Kidney Diseases, 2021, 77, 226-234.	2.1	6
60	Modeling Effects of Immunosuppressive Drugs on Human Hearts Using Induced Pluripotent Stem Cell–Derived Cardiac Organoids and Single-Cell RNA Sequencing. Circulation, 2022, 145, 1367-1369.	1.6	6
61	Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008613.	1.6	5
62	The Stanford acute heart failure symptom score for patients hospitalized with heart failure. Journal of Heart and Lung Transplantation, 2020, 39, 1250-1259.	0.3	4
63	Predicting Where Patients Will Be, Rather Than Just Seeing Where They Are. Circulation, 2020, 141, 1968-1970.	1.6	4
64	Long-Term Neurocognitive Outcome inÂPatients With Continuous Flow LeftÂVentricular Assist Device. JACC: Heart Failure, 2021, 9, 839-851.	1.9	4
65	Impact of using higher-risk donor hearts for candidates with pre-transplant mechanical circulatory support. Journal of Heart and Lung Transplantation, 2022, 41, 237-243.	0.3	4
66	Improving nutrition practices for postoperative highâ€risk heart transplant and ventricular assist device implant patients in circulatory compromise: A quality improvement pre– and post–protocol intervention outcome study. Nutrition in Clinical Practice, 2022, 37, 677-697.	1.1	4
67	A novel therapy for an unusual problem: lLâ€1 receptor antagonist for recurrent postâ€transplant pericarditis. Clinical Transplantation, 2019, 33, e13699.	0.8	3
68	Tolerability of Sacubitril/Valsartan in Patients With Durable Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, e44-e45.	0.9	3
69	New Horizons on the 50th Anniversary of Heart Transplantation in Canada: "Where There Is Death, There Is Hope― Canadian Journal of Cardiology, 2018, 34, 694-695.	0.8	2
70	Cardiopulmonary Exercise Testing With Echocardiography to Assess Recovery in Patients With Ventricular Assist Devices. ASAIO Journal, 2021, Publish Ahead of Print, 1134-1138.	0.9	2
71	Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?. ESC Heart Failure, 2021, 8, 2365-2367.	1.4	2
72	Ethical decision-making in simultaneous heart–liver transplantation. Current Opinion in Organ Transplantation, 2020, 25, 519-525.	0.8	1

#	Article	IF	CITATIONS
73	2019 STS/Intermacs Annual Report Writing Committee's Response. Annals of Thoracic Surgery, 2021, 111, 734.	0.7	1
74	Implantable hemodynamic monitoring and management of left ventricular assist devices: optimal or optional? JTCVS Open, 2021, , .	0.2	1
75	What If the Destination Is Transplant? Outcomes of Destination Therapy Patients Who Were Transplanted. ASAIO Journal, 2021, Publish Ahead of Print, 178-183.	0.9	0
76	Classifying and Risk Stratifying HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 1189-1191.	2.3	0